- Home
- AMWD vs INBX Comparison
AMWD vs INBX Comparison
Compare AMWD & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMWD | INBX |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United States |
| Employees | N/A | 161 |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.8M | 999.7M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | AMWD | INBX |
|---|---|---|
| Price | $37.56 | $68.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $63.50 | N/A |
| AVG Volume (30 Days) | ★ 197.2K | 133.5K |
| Earning Date | 02-26-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,709,585,000.00 | $200,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.56 | $10.81 |
| 52 Week High | $72.16 | $94.57 |
Technical Indicators
Market Signals| Indicator | AMWD | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 20.25 | 39.61 |
| Support Level | N/A | $28.54 |
| Resistance Level | $58.01 | $85.97 |
| Average True Range (ATR) | 1.86 | 4.35 |
| MACD | -0.57 | -0.49 |
| Stochastic Oscillator | 0.64 | 20.52 |
Price Performance
Historical ComparisonAbout AMWD American Woodmark Corporation
American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.